This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
CG Oncology is a clinical-stage biopharmaceutical company developing cancer therapeutics. As part of its drug development process, the company conducts preclinical animal testing to assess the safety and efficacy of its investigational products. This reliance on animal models is a standard, yet exclusionary, practice in the biopharmaceutical industry for companies that have not adopted or invested in alternative testing methods. The available public disclosures do not detail the scale or nature of this animal use, nor do they outline a commitment to developing or implementing non-animal testing alternatives.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.